Biotech
-
Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for…
Read More » -
Bayer drug could ease side effects of common breast cancer treatment, detailed data show
Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer application for approval.
Read More » -
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising
An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a…
Read More » -
New Summit data could slow US approval plans for PD-1/VEGF drug
Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t…
Read More » -
Cancer drugmaker iTeos to shut down
Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in…
Read More » -
FDA panel recommends keeping COVID shots targeted to same strain as last year
The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses…
Read More » -
AI tool could help doctors ID breast cancers vulnerable to Enhertu
Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New…
Read More » -
Zepzelca, Tecentriq combo extends survival in hard-to-treat lung cancer
Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung…
Read More » -
FDA sets stricter approval standards for COVID vaccines
The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, Commissioner Martin…
Read More » -
BioMarin to buy rare disease drugmaker Inozyme for $270M
The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a…
Read More »